Linked Life Data

11947915

Source:http://linkedlifedata.com/resource/pubmed/id/11947915

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-4-11
pubmed:abstractText
The effects of pravastatin (pravachol) compared with gemfibrozil on cholesterol-rich and trigylceride-rich lipoproteins were evaluated in this multi-centered trial. Following an 8-12 week prerandomization phase, 136 patients with NIDDM and hypercholesterolemia were randomized to receive either pravastatin 40 mg or gemfibrozil 1200 mg daily for 16 weeks. The reduction of total cholesterol (TC), betaquant LDL and LDL cholesterol (LDL-C) was significantly greater in patients treated with pravastatin than with gemfibrozil. However, gemofibrozil treatment resulted in a significantly greater reduction of triglyceride (TG) levels than did treatment with pravastatin. Pravastatin reduced the concentration of apoB (-19.3%, P<0.001) and cholesterol-rich Lp-B (Lp-B+Lp-B; E) particles (-19%, P<0.001) to a significantly greater extent (P<-0.001) than gemfibrozil (-4.1 and -1%, respectively). Both gemfibrozil and pravastatin reduced the concentrations of trigylceride-rich Lp-Bc (-12.2 and -13.3%, respectively) and Lp-A-II;B;C;D;E (-19 and -12.7%, respectively) particles and their characteristic apoC-III constituent (-10.0 and -7.0%, respectively). In contrast, gemfibozil has a greater lowering effect compared with pravastatin on TG levels (-29.6 vs. -6.3%, respectively). Both pravastatin and gemfibrozil significantly increased the levels of apoA-I and, with both drugs, the elevated concentrations of apoA-I were due to significantly increased levels of Lp-A-I;A-II particles. By decreasing both cholesterol-rich Lp-B and triglyceride-rich Lp-Bc particles and increasing HDL-C and Lp-A-I;A-II particles in addition to proven efficacy in decreasing coronary events in NIDDM patients, pravastatin appears to be an appropriate choice for monotherapy in a broad range of diabetic patients with Type IIA and Type IIB hyperlipoproteinemias. These results also showed that direct measurement of lipoprotein family of particles provides important information not only about the composition but also the type and number of apoA- and apoB-containing lipoprotein particles.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0021-9150
pubmed:author
pubmed:issnType
Print
pubmed:volume
162
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
201-10
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:11947915-Aged, pubmed-meshheading:11947915-Apolipoproteins, pubmed-meshheading:11947915-Cholesterol, LDL, pubmed-meshheading:11947915-Cholesterol, VLDL, pubmed-meshheading:11947915-Diabetes Mellitus, Type 2, pubmed-meshheading:11947915-Double-Blind Method, pubmed-meshheading:11947915-Drug Evaluation, pubmed-meshheading:11947915-Female, pubmed-meshheading:11947915-Follow-Up Studies, pubmed-meshheading:11947915-Gemfibrozil, pubmed-meshheading:11947915-Humans, pubmed-meshheading:11947915-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:11947915-Hyperlipoproteinemias, pubmed-meshheading:11947915-Hypolipidemic Agents, pubmed-meshheading:11947915-Lipoproteins, pubmed-meshheading:11947915-Male, pubmed-meshheading:11947915-Middle Aged, pubmed-meshheading:11947915-Patient Compliance, pubmed-meshheading:11947915-Phenotype, pubmed-meshheading:11947915-Pravastatin, pubmed-meshheading:11947915-Treatment Outcome, pubmed-meshheading:11947915-Triglycerides
pubmed:year
2002
pubmed:articleTitle
A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
pubmed:affiliation
Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste-Catherine Rd, Montreal, Que., Canada H3T 1E2. putch@total.net
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study